Loading...
NPI 1285287821 · Saint Rose, LA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Cormeum Lab Services LLC is a clinical medical laboratory provider located in Saint Rose, Louisiana. This profile covers 21 Medicare and 20 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Cormeum Lab Services LLC |
| Address | 160 James Dr E Ste 200 |
| City | Saint Rose |
| State | LA |
| ZIP | 70087 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 23, 2019 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $8.1M |
| Medicaid | $1.1M |
CORMEUM LAB SERVICES LLC is categorized as a Clinical Medical Laboratory and its billings are heavily weighted toward nucleic-acid amplified probe testing and high-throughput SARS‑CoV‑2 diagnostics. Medicare top codes include 87798, U0004, and 87481, and the broader CPT mix shows many amplified probe tests for viral and bacterial pathogens (examples include 87635, 87637, 87640, 87641, 87653 and 87500), consistent with a laboratory operation centered on molecular diagnostics and infectious-disease surveillance.
Revenue concentration is high for both payers: the top 3 Medicare codes by revenue account for 76.9% of the provider’s total Medicare revenue, and the top 3 Medicaid codes by revenue account for 82.1% of its total Medicaid revenue. For Medicare those primary drivers are 87798 ($3.5M revenue, 102K claims), U0004 ($1.6M revenue, 22.2K claims), and 87481 ($1.1M revenue, 31.9K claims); for Medicaid they are U0004 ($565.7K revenue, 21K claims), 87798 ($264.7K revenue, 6.6K claims), and U0005 ($111K revenue, 18.5K claims).
Payer mix is Medicare‑heavy: reported lifetime Medicare revenue is $8.1M versus Medicaid revenue of $1.1M, so Medicare represents the dominant revenue stream on file while Medicaid is a secondary but active payer. This split indicates the lab’s commercial scale and Medicare-facing footprint, with Medicaid contributing a smaller portion of overall billed revenue.
CORMEUM demonstrates a national-level concentration in specific tests: 87798 is ranked #14 of 1319 providers nationally (99th percentile; extreme outlier) and 87481 is ranked #9 of 1117 providers nationally (99th percentile; extreme outlier), while U0004 is ranked #2 of 259 providers nationally (100th percentile; extreme outlier). These ranks indicate the provider is an unusually large national processor for certain molecular assays, particularly non-specific amplified probe tests and specific pathogen assays.
State-level competitive standing for Medicaid is strongest in high-throughput COVID testing: U0004 ranks #2 of 19 providers in-state (94th percentile; notably above typical state volume), making CORMEUM a major in-state performer for that code. Other Medicaid codes (87798, U0005, 87481) show solid but more typical in-state positions (ranking in the middle-to-high percentiles), indicating a leading role for COVID testing locally but a more common footprint on other molecular assays.
Payment patterns differ across payers for the same services: for example, U0004 average paid per claim is $74 on Medicare versus $27 on Medicaid, and 87798 averages $34 per claim on Medicare and $40 per claim on Medicaid. These payer-level payment differences, combined with large claim volumes (e.g., 102K claims for 87798 and 22.2K claims for U0004 on Medicare), drive the observed revenue profile and underline the provider’s dependence on high-volume, lower‑per‑claim molecular testing.
The provider’s NPI was enumerated on 2019-07-23 (~7 years ago), indicating a relatively recent market entry compared with long-established labs; despite that tenure it has quickly scaled high-volume molecular testing lines. Rapid growth to national outlier status on several codes suggests a focused operational model emphasizing high-throughput molecular diagnostics rather than a broad, generalist lab service mix.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 102,030 | $30 | $3.5M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 22,220 | $70 | $1.6M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 31,890 | $30 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 21,140 | $30 | $528.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 8,000 | $30 | $271.9K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 7,740 | $30 | $263.1K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 7,600 | $30 | $258.4K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 5,470 | $30 | $186K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 1,650 | $50 | $82.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 1,520 | $30 | $51.5K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| U0004 | 1 | 10 | 11,140 | $70 | $818.4K |
| 87798 | 1 | 20 | 1,390 | $30 | $352.3K |
| 87481 | 1 | 20 | 270 | $30 | $82.9K |
| U0005 | 1 | 10 | 460 | $20 | $78.3K |
| 87471 | 1 | 10 | 1,350 | $30 | $46.3K |
| 87500 | 2 | 20 | 110 | $30 | $43.5K |
| 87641 | 2 | 20 | 130 | $30 | $38.9K |
| 87640 | 2 | 20 | 120 | $30 | $34.3K |
| 87653 | 1 | 10 | 100 | $30 | $24.6K |
| 87631 | 2 | 10 | 30 | $140 | $12.6K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 20,950 | $30 | $565.6K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 6,620 | $40 | $264.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 18,490 | $10 | $111K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 5,860 | $20 | $87.8K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 5,870 | $1 | $23.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 5,830 | $1 | $23.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,750 | $1 | $20.2K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 3,750 | $1 | $15K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 2,080 | $1 | $6.2K |
| 87471 | The lab analyst performs a test for Bartonella henselae and Bartonella quintana using amplified nucleic acid probe technique. | 1,490 | $1 | $6K |
Showing 1–10 of 20
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
20 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 4 | 10 | 350 | $20 | $668.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 12 | 90 | 650 | $40 | $404.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 3 | 20 | 690 | $20 | $359.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 3 | 30 | 390 | $20 | $285.9K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 169 | 210 | 630 | $70 | $239.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 10 | 50 | 530 | $20 | $237.6K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 104 | 190 | 1,000 | $30 | $139.9K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 49 | 170 | 640 | $30 | $138.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 20 | 130 | $40 | $137.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 104 | 190 | 900 | $30 | $137.2K |
Showing 1–10 of 20
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.